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 17 
Highlights 18 
 No in vitro model of osteoarthritis has been validated against the native disease 19 
 Cytokine and compression models are most commonly used 20 
 Cytokine based models often use concentrations far greater than values measured in vivo 21 
 Supraphysiological loads are also used often to exaggerate the response 22 
 The development of an in vitro model might require a combinatorial, multi-modal approach 23 
Abstract 24 
Osteoarthritis (OA) is a prevalent disease of most mammalian species and is a 25 
significant cause of welfare and economic morbidity in affected individuals and populations. 26 
In vitro models of osteoarthritis are vital to advance research into the causes of the disease, 27 
and the subsequent design and testing of potential therapeutics. However, a plethora of in 28 
vitro models have been used by researchers but with no consensus on the most appropriate 29 
model. Models attempt to mimic factors and conditions which initiate OA, or dissect the 30 
pathways active in the disease. Underlying uncertainty as to the cause of OA and the different 31 
attributes of isolated cells and tissues used mean that similar models may produce differing 32 
results and can differ from the naturally occurring disease.  33 
This review article assesses a selection of the in vitro models currently used in OA 34 
research, and considers the merits of each. Particular focus is placed on the more prevalent 35 
cytokine stimulation and load-based models. A brief review of the mechanism of these 36 
models is given, with their relevance to the naturally occurring disease. Most in vitro models 37 
have used supraphysiological loads or cytokine concentrations (compared with the natural 38 
disease) in order to impart a timely response from the cells or tissue assessed. Whilst models 39 
inducing OA-like pathology with a single stimulus can answer important biological questions 40 
about the behaviour of cells and tissues, the development of combinatorial models 41 
encompassing different physiological and molecular aspects of the disease should more 42 
accurately reflect the pathogenesis of the naturally occurring disease. 43 
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Introduction 46 
Osteoarthritis (OA) is the most common form of arthritis and is one of the leading 47 
causes of disability worldwide. Most mammalian populations are affected, including humans 48 
and domesticated animal species including sheep (Vandeweerd et al., 2013), horses (Ireland 49 
et al., 2013), cats (Clarke et al., 2005) and dogs (Clements et al., 2009). Estimates in human 50 
populations suggest that 9.6% of men and 18% of women over the age of 60 years have 51 
symptomatic OA (Woolf and Pfleger, 2010). In 2006-2007 in the United Kingdom 94% of 52 
hip and 97% of knee replacements were carried out for relief of OA, costing an estimated 53 
£809 million
1
. Consequently OA is a major concern, particularly in ageing populations 54 
(Nguyen et al., 2011). 55 
 56 
Symptoms of OA most commonly include pain, swelling and stiffness in the affected 57 
joint, resulting from the degradation of articular cartilage (Madry et al., 2012), changes in the 58 
composition of the subchondral bone (Sniekers et al., 2008; Saito et al., 2012) and synovitis 59 
(Goldhammer et al., 2010). Historically, OA was primarily observed in elderly individuals 60 
which led to the idea that OA was a ‘wear-and-tear’ type disease (Berenbaum, 2013). 61 
However, this idea is now less favoured because younger patients often display symptoms of 62 
OA secondary to injuries or because of a genetic predisposition to the disease (Da Silva et al., 63 
2009).  64 
 65 
OA is a multifactorial disorder and no single aetiological mechanism has been found 66 
common to all forms of the disease (Iliopoulos et al., 2007). Large genetic studies have 67 
identified numerous genetic risks for OA (Reynard and Loughlin, 2013), although the odds 68 
ratios for most single nucleotide polymorphism (SNP) associations are low, and rarely do 69 
                                                          
1
See: http://www.arthritisresearchuk.org/arthritis-information/data-and-statistics/osteoarthritis.aspx (accessed 24 
November, 2014) 
£1 = approx. US$1.50, €1.36 at 06 April 2015. 
Page 4 of 36
5 
 
they apply to more than one form of the disease. The mechanisms which underpin genetic 70 
risks are often unidentified, and in vitro models are critical if we are to expand our 71 
understanding of their role in disease progression. 72 
 73 
Both in vivo and in vitro models of OA have been used in the past (Goldring et al., 74 
2008; Grenier et al., 2014; Fang and Beier, 2014). Whilst models can be broadly grouped 75 
according to the primary mechanism by which the catabolic process is stimulated, each with 76 
their own strengths and weaknesses (Table 1), subtle variations mean that an almost infinite 77 
number of variations exist for a single model (Benam et al., 2015). Similarly, whilst in vivo 78 
models may give the most accurate reflection of the naturally-occurring whole-joint disease, 79 
the ease of manipulating an in vitro system, as well as a shift towards the 3R philosophy of 80 
refining, reducing and replacing the use of animals in animal science (Madden et al., 2012) 81 
makes in vitro modelling of the disease desirable. The observation that spontaneous OA in 82 
domestic animals has a similar pathogenesis to that observed in humans (Clements et al., 83 
2006), and the availability of naturally-occurring, early-stage diseased tissue, for example at 84 
slaughter in food animal species or following a veterinary surgical intervention in companion 85 
animals (Clements et al., 2009) makes domestic animals an important source of clinical 86 
material for such models. 87 
 88 
Additionally, models of OA offer the opportunity to study early features of the 89 
development of the disease, prior to the development of a fulminant catabolic process, which 90 
have been difficult to dissect because of the lack of available tissue from early disease and the 91 
limited molecular changes associated with it (Aigner et al., 2006). No consensus on the most 92 
appropriate model for the representation of particular features of OA has been made, as each 93 
model has its own mechanisms for the induction of a general catabolic process. Furthermore, 94 
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the molecular phenotypes of different forms of OA also show distinct differences (Xu et al., 95 
2012), and such subtleties can be considered when designing models of OA rather than 96 
ignoring them when using more general in vitro models.  97 
 98 
The relevance of in vitro models to clinical disease always needs to be interpreted 99 
with caution. For example, numerous publications report the chondroprotective effects of 100 
glucosamine and chondroitin sulphate on in vitro models (Dechant et al., 2005; Chan et al., 101 
2007), but clinical trials have failed to show such effects in vivo (Wandel et al., 2010; 102 
Sawitzke et al., 2010). Whilst some effects of the differences can be ascribed to delivery, 103 
complexity, duration and variation of the phenotype, ultimately in vitro models should be 104 
designed to better reflect the natural in vivo disease. This particularly applies to the disease 105 
state, where almost all models are designed to replicate the symptoms of end-stage OA with 106 
little or no regard to the early disease where chondroprotection is likely to yield greater 107 
benefits.  108 
 109 
This review summarises the two most commonly used in vitro models of OA, namely, 110 
cytokine-based models and load-based models, and then discusses their various merits and 111 
how they reflect the naturally-occurring processes.  112 
 113 
Cytokine induction of OA-like processes 114 
Classic research on OA has focused on cartilage, but other tissues such as bone, 115 
synovium, ligament, infrapatellar fat (Maccoux et al., 2007) and periarticular muscles (Geyer 116 
et al., 2009) are also involved (Fig. 1). The changes seen in these tissues are attributed to 117 
diffusible factors, including proteolytic enzymes, such as matrix metalloproteinases (MMPs) 118 
and members of the ‘a disintegrin and metalloproteinase with thrombospondin-motif’ 119 
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(ADAMTS) family that are present in the joint environment during the disease (Little et al., 120 
2005; Clements et al., 2006).  121 
 122 
Cytokines in OA 123 
During OA, synoviocytes, mononuclear cells or chondrocytes may increase their 124 
expression of catabolic proteins (Fernandes et al., 2002) following stimuli such as cytokine or 125 
chemokine exposure, including interleukin (IL)-1β and tumour necrosis factor (TNF)-α, 126 
which are present in the joint following synovial inflammation (Sohn et al., 2012). Pro-127 
inflammatory cytokines make ideal candidates for the induction of OA-like biological 128 
changes in articular cells or tissues in culture, in which temporal and concentration effects 129 
can be explored. 130 
 131 
Models of OA where cytokines are the primary method of induction are very common 132 
and are generally well understood. The model is usually inexpensive and is very easily 133 
manipulated. The ability to expand cells in vitro also means that many replicates are possible, 134 
allowing multiple hypotheses to be tested from single sources of tissue. Nevertheless, cells in 135 
culture (particularly chondrocytes) are prone to dedifferentiate to fibroblasts after only a 136 
small number of passages (Caron et al., 2012; Minegishi et al., 2013), and isolating cells from 137 
their matrix removes possible matrix-effects. Additionally, inter-tissue crosstalk is difficult to 138 
characterise in vitro and both time- and concentration-dependent effects are not well 139 
understood (Table 1). 140 
 141 
Evidence for a role of IL-1β in OA is well established, and it has been used as a 142 
potential therapeutic target, for example through the design of vectors activated by IL-1 that 143 
protect against its catabolic effect (Campbell et al., 2005) or through the antagonism of the 144 
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IL-1 receptor (IL-1R) (Chevalier et al., 2009). Exposure to IL-1β stimulates chondrocytes and 145 
synovial cells to produce catabolic proteases (Maccoux et al., 2007) with apocrine signalling 146 
further enhancing MMP release and the resulting degradative cascade. The catabolic response 147 
can be blocked by the inhibition of IL-1β through antagonism with the IL1-R antagonist (IL-148 
1Ra) (Bujak and Frangogiannis, 2009).  149 
 150 
Inflammatory molecules produced by chondrocytes in response to IL-1β, include 151 
prostaglandin (PG)E2, cyclooxygenase (COX)-2, IL-6, IL-8 and leukaemia inhibitory factor 152 
(LIF). IL-1β also leads to the accumulation of reactive oxygen species, through expression of 153 
inducible nitric oxide synthase (iNOS) by the transcription factor nuclear factor kappa B (NF-154 
κB), ultimately leading to apoptosis (Fig. 2a). This mechanism can also be accelerated by IL-155 
1β-mediated damage to mitochondrial DNA, leading to a further release of reactive oxygen 156 
species and enhancing apoptosis (Loeser, 2011). 157 
 158 
IL-1 plays a role in bone pathophysiology relevant to OA, particularly IL-1α which is 159 
also known as osteoclast activating factor (Lee et al., 2010). In bone, there is an increase in 160 
the activity of PGE2 in osteoblasts and stromal cells, as well as an increase in the expression 161 
of receptor activator of NF-κB Ligand (RANKL). RANKL is critically involved in the 162 
activation, maturation and survival of osteoclasts (Tanaka et al., 2005). IL-1 has also been 163 
shown to induce multinucleation of osteoclasts, thus potentiating the function of the cells. In 164 
vivo, when adult rats were injected with a moderate amount of IL-1β (1 µg/kg bodyweight), 165 
an increase in serum and urinary Ca
2+ 
concentration was noted, as well as an increase in 166 
osteoclast number, implying an increase in bone resorption (Nguyen et al., 1991) 167 
 168 
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TNF-α has also been used to induce OA-like changes in in vitro experiments, because 169 
it is found in diseased synovial fluid (Horiuchi et al., 1999; Fujita et al., 2005), and is able to 170 
induce catabolism and inhibit anabolic pathways in joint tissues and cartilage cells (Liacini et 171 
al., 2003). While IL-1β and TNF-α are the most commonly used cytokines in modelling OA, 172 
other cytokines may also play important roles. Concentrations of IL-6, IL-8, vascular 173 
endothelial growth factor (VEGF) and monocyte chemoattractant protein-1 (MCP-1) are all 174 
increased in the synovial fluid of OA joints (Sohn et al., 2012). Osteoclasts are recruited by 175 
IL-6, and thus it may be an important modular of the bone remodelling observed in OA 176 
(Silfverswärd et al., 2004). However, in model designs, these cytokines are rarely considered, 177 
possibly because they are characterised as chondrocyte-derived and thus they can be induced 178 
by other cytokines such as IL-1β or TNF-α (Bunning et al., 1990). Using cytokines in 179 
combination may allow for the induction of OA-like cell and tissue responses that more 180 
closely replicate the natural disease, particularly in lieu of synovial effects in the model 181 
design.  182 
 183 
In vivo determination of cytokine concentrations  184 
Cytokine-based models use a wide variety of concentrations and durations of cytokine 185 
stimulation, namely those which produce a measurable downstream effect, rather than a 186 
concentration that reflects that in naturally occurring disease. Besides, OA is a slowly-187 
progressing disease, and relatively small increases in cytokine concentrations have been 188 
identified in naturally-affected joints.  189 
  190 
When OA synovial fluid is assayed, the quantities of IL-1 (< 2 ng/mL) and TNF 191 
(almost 3 ng/mL) are highly variable between experiments, but are low in comparison with 192 
those used to exert an effect in vitro (Table 2). The variation in physiological concentrations 193 
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is evident and may be the result of several factors, including the method used to quantify the 194 
cytokines, or the phenotype of the disease. In contrast, the concentrations used in models are 195 
typically much higher at up to 100 ng/mL of IL-1β (Macrory et al., 2009), and up to 50 196 
ng/mL of TNF-α (Gabriel et al., 2010).  197 
 198 
Explant-based models of cytokine stimulation 199 
Explant-based models are simple and easy to produce, and have the major advantage 200 
that they can be used to examine the response of cells in their natural extracellular matrix 201 
and, once removed from their extracellular matrix, the cell phenotype is altered (Zien et al., 202 
2001). Using explanted tissue also allows features such as matrix degradation to be observed. 203 
However, the use of tissue explants creates new problems; for example, cells at the explant 204 
edge die (Hunziker and Quinn, 2003; Gilbert et al., 2009), there are limitations to the number 205 
of samples which can be obtained from the same source and more than one tissue might be 206 
required to maintain viability (Amin et al., 2009). 207 
 208 
  Cartilage is highly sensitive to TNF-α and physiologically relevant concentrations as 209 
low as 0.25 ng/mL (Westacott et al., 1990) are sufficient to increase the release of 210 
glycosaminoglycans (GAGs) from OA cartilage (human) when compared with healthy 211 
cartilage in a 14 day period (Westacott et al., 2000). Species-specific differences may exist in 212 
the stimulation required to elicit a particular response (such as GAG release); thus, GAG 213 
release from feline cartilage explants requires stimulation with both recombinant human IL-214 
1β and oncostatin-M (OSM) in combination (Gabriel et al., 2010), although a feline-specific 215 
stimulus may have elicited a different response. 216 
 217 
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A possible autocrine network has been suggested because both IL-β and TNF-α show 218 
strong positive protein staining in the superficial zone of cartilage as well as in the synovial 219 
fluid in late-stage OA. Meanwhile, deep zone cells only demonstrate marginal staining in the 220 
most severe cases (Tetlow et al., 2001), illustrating the differential responses of chondrocytes 221 
in disease. Notably, the early stages of disease rarely demonstrate any chondrocyte 222 
expression of cytokines, implying that any inflammatory cytokines present in the joint at the 223 
early stage of the disease are most likely to be synovial in origin (Tetlow et al., 2001). 224 
  225 
Chondrocyte culture-based cytokine models 226 
The choice of whether to use a monolayer, a cell scaffold or intact tissue will 227 
influence the cells’ response to the cytokine stimulus applied. The sensitivity of chondrocytes 228 
to their molecular and loading environment dictates that ideally they should not be isolated 229 
from their matrix, or if they are, the matrix in which they are embedded should closely match 230 
the behaviour of normal, healthy tissue. However, the low cellularity of cartilage tissue 231 
necessitates the demand for large explants, thereby reducing the number of replicates which 232 
can be obtained from a single tissue source. Monolayer cultures allow the expansion of the 233 
cellular resource, although this is finite for tissues such as cartilage (Nicholson et al., 2007), 234 
as the cell phenotype changes in monolayer culture (Zien et al., 2001). 235 
 236 
The ease of using chondrocytes in monolayer combined with their rapid response to 237 
cytokine stimulation has resulted in this being the most widely used model. Numerous 238 
models that use cytokines added to cell or tissue culture medium have been shown to produce 239 
OA-like responses in chondrocytes in monolayer, such as a decrease in the expression of type 240 
2 collagen and aggrecan, and an increase in the expression of MMP-13, across multiple 241 
species (Miyaki et al., 2009; Novakofski et al., 2012; Yang et al., 2014). 242 
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  243 
Alternatively, stimulating chondrocytes with the synovial fluid from OA patients 244 
(Hoff et al., 2013), a more physiologically-relevant stimulus, produces similar results, 245 
including the expression of the pro-inflammatory cytokines IL-6, IL-8, IFN-γ, MCP-1, 246 
granulocyte-colony stimulating factor (G-CSF) and VEGF. However, this method of 247 
stimulation is also limited by the imprecise understanding of the relative contribution of 248 
different mediators which are driving catabolism in this model, and the lack of repeatability 249 
because of the limited synovial fluid volume that can be obtained from a single source. 250 
 251 
Co-culture-based cytokine models  252 
Recognising that OA is a disease that affects and involves the interaction between 253 
multiple tissues are co-culture experiments that permit the study of these interactions in vitro. 254 
Cytokine or osmotic pressure stimuli can be easily applied to co-culture models, though the 255 
tissues might require different culture conditions, necessitating some compromise on the 256 
culture conditions used when cultured together. The co-culture of synovial membrane with 257 
chondrocytes is one method by which the complexity of the pro-inflammatory cascade can be 258 
reproduced in vitro, because synovium is the primary source of these mediators (Ushiyama et 259 
al., 2003).  260 
 261 
Co-culturing synovium from OA patients with healthy cartilage explants produces an 262 
increase in the expression of IL-1, IL-4, IL-7, IL-8, IL-10, IL-13 and osteoprotegerin (OPG), 263 
similar to synovial fluid from OA joints, as well as reducing GAG production in the cartilage 264 
(Beekhuizen et al., 2011). Whilst it may be desirable to use synovium to model OA in vitro, it 265 
is composed of two different, but interacting, cell types and shows highly variable lesion 266 
patterns both across different OA joints, and within a single joint with clinical OA (Rhodes et 267 
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al., 2005; Goldhammer et al., 2010; Smith, 2011). Consequently, deconstructing the effects 268 
within the synovial co-culture model is complex, although characterisation of the factors 269 
responsible for the response will help to standardise across experiments. The use of bone in 270 
co-culture experiments is also important, because it appears to have a role in maintaining the 271 
long-term viability of chondrocytes in the superficial zone of articular cartilage (Amin et al., 272 
2009).  273 
 274 
Bone cytokine models 275 
 Evaluation of the response of bone to cytokine stimulation in models of OA is scarce, 276 
which is unsurprising because it is difficult to ascertain the precise cytokine environment to 277 
which bone cells are exposed to in OA. Most data on cytokine roles in bone focus on the 278 
specific roles of TNF-α, IL-6 and IL-1 release during osteocyte injury (Komori, 2013). 279 
Further, generation of RANKL is induced by IL-6 and IL-1, and mice lacking RANKL 280 
completely lack osteoclasts (Kong et al., 1999). Osteoclasts driven to apoptosis release 281 
soluble RANKL, and conditioned media from these cells further induce osteoclastogenesis 282 
(Al-Dujaili et al., 2011). Notably, bone plays a larger role than previously considered in 283 
cartilage health, and removal of cartilage explants from the underlying bone tissue leads to a 284 
higher percentage of cell death in chondrocytes than if chondrocytes were left attached to the 285 
bone (Amin et al., 2009).  286 
 287 
Mouse calvarial cultures incubated with IL-1 showed bone resorption, demonstrating 288 
that cytokines act on cultured bone (Gowen et al., 1983), and cultured osteoblasts actively 289 
synthesised NO in response to IL-1α in a dose-dependent fashion, although IL-1β, TNF-α and 290 
IFN-γ failed to elicit a response (Ake et al., 1994). Evidently, cytokines play a role in bone 291 
turnover, and bone is responsive to inflammatory stimuli. IL-1β has been shown to induce the 292 
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release of PGE2, MMP-3 and MMP-13 from osteoblasts (Pecchi et al., 2012), although this 293 
can be inhibited with chondroitin sulphate.  294 
 295 
Load-based models of inducing OA 296 
Chondrocytes are sensitive to load, and must always be under sufficient force to 297 
maintain extracellular matrix homeostasis, yet below that which induces apoptosis or 298 
stimulates an inflammatory cascade within the tissue (Henrotin et al., 2012). Subchondral 299 
bone is also mechanosensing, and responds in vivo by changing its thickness and reducing its 300 
resorption when loading is increased (Murray et al., 2001). Identifying the load thresholds 301 
that alter the balance from maintenance of homeostasis to injury is important to our 302 
understanding of the magnitude of a beneficial or deleterious load. 303 
 304 
Load models are easily manipulated and, as a result, high throughput experiments can 305 
be performed. Signalling pathways associated with mechanotransduction are becoming well 306 
understood (Millward-Sadler and Salter, 2004; Mobasheri et al., 2005), allowing better 307 
appreciation of the processes associated with this model. Removing cells from their native 308 
matrix and embedding them into an artificial scaffold alters, at least theoretically, the native 309 
signalling network, and the force used in the experiment is innately dependent on the ability 310 
of the scaffold to withstand that force.  311 
 312 
Cell loading models require high cell numbers that might not be available from some 313 
sources. Using entire tissues overcomes this problem, and allows cells to use natural cell-314 
matrix interactions and cross-tissue communication as well as much greater forces. 315 
Conversely, native tissue experiments are limited to larger species and lower numbers of 316 
replicates. Additionally, cells have been shown to undergo substantial cell death at the cut 317 
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edge (Huntley et al., 2005; Huntley et al., 2005a) so distorting observations at these sites 318 
(Table 1). 319 
 320 
In vivo determination of cartilage load 321 
 Several in vivo studies have attempted to determine the physiological pressures 322 
experienced by articular cartilage during loading. The pressure passing through the load-323 
bearing region of a human acetabular prosthesis has been determined to be approximately 3.5 324 
MPa during locomotion (Hodge et al. 1989), and the articular contact pressure of the human 325 
knee does not exceed 8 MPa, even when the menisci have been removed (Fukubayashi and 326 
Kurosawa, 1980). Loads of a similar magnitude have been reported in both the medial and 327 
lateral compartments of canine elbow joints, with mean contact pressures between 3.0 and 4.0 328 
MPa and peak pressures between 6.6 and 9.1 MPa (Cuddy et al., 2012). These data suggest 329 
that the articular loading experienced by different joints in different species are 330 
physiologically comparable, and concurs with estimates of the articular cartilage compressive 331 
stress in different mammalian species, which only vary within one order of magnitude from 332 
mice to cows (Simon, 1970). 333 
  334 
Chondrocytes sense the loading of their environment through integrin receptors 335 
(Bader et al., 2011). When activated, the integrins stimulate stress pathways leading to 336 
cytoskeletal disruption and release of inflammatory cytokines, such as IL-1β and TNF-α 337 
(Valhmu et al., 1998; Durrant et al., 1999; Bader et al., 2011). Cytokine-induced proteolytic 338 
enzyme release is mediated by nitric oxide, PGE2 and reactive oxygen species. The 339 
extracellular proteins cleaved by the activated proteases are then capable of further induction 340 
of both proinflammatory cytokines and matrix proteases, though the receptors activated by 341 
collagen fragments remain elusive (Klatt et al., 2009).  342 
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 343 
The signalling pathways induced by static loading and cytokine induction are similar 344 
and the mechanism that governs both is similar in both models (Fig. 2b). The compression 345 
pathway, however, appears reliant on the magnitude and duration of the stress (Fanning et al., 346 
2003).  347 
 348 
Explant based models of cartilage loading 349 
The use of tissue explants, assessing the response of cells embedded in the natural 350 
matrix, is the simplest method for assessing the effects of load. Load is applied to tissue 351 
explants through various methods, based on the variable in question. Most typically, ‘drop 352 
towers’ in which a free weight is released from a predetermined height onto the tissue are 353 
used to impart a single impact load. This is believed to replicate the development of ‘post 354 
traumatic’ OA, which occurs following an injurious articular load. Load can also be applied 355 
in a cyclical manner with devices such as pneumatic or hydraulic loading chambers.  356 
 357 
Static loading can induce similar deleterious changes in cartilage explants when 358 
applied at an appropriate magnitude. For example a compressive strain of 50% applied to a 359 
cartilage explant results in a decrease in the synthesis of collagen type II and proteoglycans 360 
(Chen et al., 2001). Static compression of calf patellofemoral cartilage to 25% or 50% strain 361 
for 24 h produces deleterious changes in cartilage metabolism, resulting in an increase in 362 
expression of MMP3, 9 and 13 mRNA and decrease in COL2A1 and aggrecan (ACAN) within 363 
1-2 h post loading (Fitzgerald et al., 2004). IL-1 receptor activation and activation of the 364 
extracellular-signal related kinase 1/2 (ERK1/2), p38, mitogen-associated protein kinase 365 
(MAPK) family member pathways in a time-dependent manner meditate these changes 366 
(Fanning et al. 2003). 367 
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 368 
A load equivalent to 1.5 × bodyweight placed on a human knee joint caused only 10% 369 
strain in the patellofemoral cartilage following 10 min of static loading (Wong and Sah, 370 
2010). Similarly, intact human femoral head cartilage loaded to the equivalent of a single leg 371 
stance (less than 2.3 × bodyweight) is subject to a strain of 33% (Greaves et al., 2010). 372 
Consequently the use of higher strains in in vitro models exaggerates the maximal normal 373 
physiological load experienced by a joint in vivo, although this reflects the requirement to 374 
induce an effect within a shorter timeframe. Furthermore, the elastic (Young’s) modulus 375 
varies across cartilage within a joint (Shepherd and Seedhom, 1999), and thus the load 376 
required to induce a specific strain, or strain produced from a specific load will also differ 377 
across samples from the same joint. 378 
  379 
In vitro studies have been used to determine the critical stress thresholds of cartilage 380 
explant, in which apoptosis, collagen degradation and nitrite accumulation are observed. 381 
Values range between 4.5 MPa for cyclic loading (six compressions to a final strain of 30-382 
50%, held for 5 min rested for 25 min, Loening et al., 2000) and 15 MPa for a single impact 383 
load (Torzilli et al., 1999) for bovine cartilage, although the results between experiments are 384 
highly variable. Notably, bovine cartilage explants subjected to a 0.5 MPa cyclic loading 385 
increase proteoglycan synthesis across various cycle lengths (Parkkinen et al., 1992) 386 
supporting the hypothesis that moderate loading is beneficial to cartilage health. 387 
  388 
Chondrocyte culture-based loading models 389 
 The response of cells to load can be dissected further by isolating cells in culture, 390 
embedding them in an artificial matrix, and compressing them using a bioreactor. This has 391 
the advantage of permitting very precise changes in loading parameters, as it is highly 392 
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reproducible, as well as looking at the effects of different matrices on the cellular response. 393 
However, a large caveat to such experiments is that the cell response observed in vitro may 394 
not represent that observed in vivo where the interaction of the matrix is critical to the effect 395 
produced.  396 
 397 
In vitro loading of isolated chondrocytes seeded in a 3-dimensional (3-D) culture 398 
(typically agarose) results in both an increase in cell proliferation and proteoglycan synthesis 399 
when cyclically loaded at a physiological strain of 15% (Lee and Bader, 1997). 3-D culture 400 
also allows for the application of bi-axial cyclic loading (direct compression or tension, and 401 
shear) (Pingguan-Murphy and Nawi, 2012), and addresses the observation that in vivo several 402 
loads may simultaneously impact on a joint during normal activity. When subjected to biaxial 403 
loading (10% compressive strain with 1% sheer strain) for two 12 h periods, separated by a 404 
12 h resting period, both cell proliferation and an increase in GAG production were observed, 405 
demonstrating the importance of closely representing the joint environment in in vitro 406 
experiments. 407 
 408 
Cyclic loading of bovine chondrocyte-embedded calcium polyphosphate scaffolds at 409 
1 kPa and 1 Hz for 30 min, activates Erk1/2 and c-Jun N-terminal kinase (JNK) as seen with 410 
static loading, and causes an increase in activator protein-1 (AP-1) binding. This stimulus 411 
induces MMP-3 and 13 expression and results in MMP-13 mediated extracellular matrix 412 
(ECM) degradation. However, following the loss of functional tissue, collagen type II and 413 
aggrecan gene expression occurs after 12 h, and synthesis occurs by 24 h post loading (Fig. 414 
2c) (De Croos et al., 2006). 415 
 416 
Co-culture based loading models 417 
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Co-culture methods have been used to explore the effect of loading on articular 418 
tissues in parallel, although they are challenged by the necessity to use different culture 419 
conditions for each tissue, or to compromise the culture conditions. For example, alginate-420 
embedded chondrocytes cultured on a porous filter above mechanically stretched osteoblasts 421 
become more hypertrophic during stimulation of the osteoblasts. This change was most 422 
pronounced when the osteoblasts were subjected to tensile loads, suggesting molecular 423 
‘cross-talk’ occurs between the two cell types in response to mechanical stress in bone (Lin et 424 
al., 2010).  425 
 426 
Co-culture of OA osteoblasts with healthy alginate bead-embedded chondrocytes 427 
result in a phenotypic shift to chondrocyte hypertrophy and matrix mineralisation, which does 428 
not occur with healthy osteoblasts stimulated with IL-1, IL-6 or OSM (Sanchez et al 2005). 429 
This demonstrates the limits of artificially stimulating cells and the phenotypic differences of 430 
naturally-diseased cells and highlights the need for better characterisation of the soluble 431 
factors released by these cells as well as better definition of the molecular stimulation 432 
required to induce the OA phenotype in healthy cells.  433 
 434 
Bone loading models 435 
Osteocytes are the major mechanosensors of bone, although they are rarely included 436 
in models of OA because they are notoriously difficult to culture in vitro. Analysis of the 437 
osteocyte (in contrast to osteoblast) response to compression has been hindered due to this 438 
challenge (Kato et al., 1997). Osteocyte cell lines seeded into type I collagen gels layered 439 
with osteoblasts on their surface respond to mechanical loading, with co-cultured constructs 440 
increasing type I collagen expression with loading, and osteocyte embedded gels expressing 441 
PGE2 after mechanical stimulation (Vazquez et al., 2014).  442 
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 443 
Relevance of load: From in vivo to in vitro models 444 
The validity of a loading model depends, at least to some extent, on its relationship 445 
with the natural environment of the joint and its loading in vivo. The loading parameters of a 446 
selection of cell and tissue loading models are presented in Table 3. The use of scaffolds can 447 
impart some structure to the cells for culture-based models, and permit cyclic loading of 448 
isolated cells, albeit within ranges that are governed by the strength of the matrix in which 449 
they are embedded. 450 
 451 
The heterogeneity of the cartilage structure means that precise reconstruction of the 452 
tissue in vitro may not be possible, and so compromises must be made when constructing a 453 
load based model (Gannon et al., 2012). The individual phenotype of each chondrocyte is 454 
related to their location in the tissue (Fujioka et al., 2013; Schuurman et al., 2015) and 455 
therefore in homogeneous tissue models, chondrocytes may not behave in the same manner. 456 
 457 
Future directions  458 
The multifactorial nature of OA should be considered when designing a model to 459 
reproduce it, even if it is only testing a single parameter, such as the response to a load or 460 
catabolic stimulus. A deeper understanding of the pathways evoked in in vitro models, and 461 
their relevance to the changes seen in naturally-occurring OA phenotypes is important in 462 
order to improve the translational relevance of the conclusions drawn.  463 
 464 
To date the vast majority of explant- and culture-based models have assessed cartilage 465 
in isolation. While this might reflect the ease of manipulating cartilage and the resilience of 466 
chondrocytes in cell culture, progress in tissue engineering and cell culture techniques will 467 
Page 20 of 36
21 
 
allow for the development of more advanced models including other cell types. The 468 
responsiveness of bone to stimuli, and the cross talk that occurs between the different tissues 469 
in OA joints dictate that models should consider the role of multiple tissues when assessing 470 
the response to a given stimulus so as to enable more meaningful translation to the 471 
anticipated response in vivo. 472 
 473 
There is no all-encompassing model that is suitable for all studies of OA, and no 474 
single model can be used to perfectly simulate naturally-occurring events. Whilst models 475 
seek to answer specific biological questions, more standardised end-points for the molecular 476 
and physiological parameters assessed are necessary, as at present it is impossible to directly 477 
compare the outcomes of the many in vitro OA models published in the scientific literature.  478 
 479 
Other areas of articular health research, such as those looking at histological 480 
assessments of cartilage repair and damage
2
 (Glasson et al., 2010), have developed guidelines 481 
upon which assessments should be made through the consensus of experts and the publication 482 
of their recommendations. In molecular biology, similar guidelines have been developed for 483 
performing microarray and quantitative polymerase chain reaction studies (Brazma et al., 484 
2001; Bustin et al., 2009). Whilst the in vitro models of OA have many different functions 485 
and outcomes, guidelines could still be developed to determine the endpoints which are 486 
matrix- and chondro-protective, and the minimum number of features of a model (such as 487 
measures of matrix release and turnover, transcription changes and/or cellular morphometric 488 
changes) which are agreed to represent an ‘OA-like’ scenario. Similarly, models seeking to 489 
investigate the pathogenesis of OA must justify the nature of stimulatory conditions, relative 490 
to the in vivo disease, beyond simply that required to produce a response. At the very least in 491 
                                                          
2
 See: http://www.cartilage.org/_files/contentmanagement/ICRS_evaluation.pdf (accessed 7 April, 2015)  
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vitro models should be standardised to a particular disease phenotype, with reasoning for the 492 
source of the cells and/or tissues used and the outcomes to be measured, as there is no single 493 
OA phenotype which can be encompassed by all models.  494 
 495 
Conclusions 496 
The molecular pathways underpinning cytokine-stimulation and load-based in vitro 497 
models of disease are similar. The combination of different models types may permit the use 498 
of stimuli which are physiologically relevant, and which allow us to understand the 499 
development and progression of the disease, particularly the early phase, rather than simply 500 
the catastrophic downstream events after it has begun. Standardisation of the approaches, 501 
both within and between different species will allow the wider applicability of results 502 
between studies, which in turn will enhance our understanding of the disease. 503 
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Tables 886 
Table 1 887 
Advantages and disadvantages of some of the most commonly used in vitro models 888 
Model 
Type 
Variables that can 
be applied 
Advantages Disadvantages Examples 
Monolayer 
culture 
Cytokine stimulation, 
osmotic pressure 
Allows expansion of 
cellular resource from a 
single sample, 
investigation of distinct 
pathways in isolation 
Altered phenotype of 
isolated cells due to 
isolation from tissue and 
absence of normal 
extracellular matrix 
(Sylvester et al., 
2012; Novakofski 
et al., 2012) 
Co-culture Cytokine stimulation, 
osmotic pressure 
Considers cross-talk 
between cell types 
Altered phenotype of 
isolated cells 
Different cell types 
require different culture 
conditions, or 
compromise if culture 
together  
(Lin et al., 2010; 
Beekhuizen et al., 
2011; Vazquez et 
al., 2014) 
3D-culture Cytokine stimulation, 
osmotic pressure, 
physical injury and 
loading regimens. 
Affords structure and 
force to sensitive cells. 
Magnitude of force is 
scaffold dependent, and 
may not reflect that of 
the normal tissue 
Isolation and expansion 
of cell types first 
(Mizuno and 
Ogawa, 2011; 
Bougault et al., 
2012; Pingguan-
Murphy and 
Nawi, 2012) 
Explant Cytokine stimulation, 
osmotic pressure, 
physical injury and 
loading regimens. 
Inexpensive, easily 
produced, cells 
maintained in normal 
extracellular matrix. 
Cell death at cut edge of 
tissue, few replicates 
available from same 
source, more than one 
tissue type may be 
required to maintain 
viability, physical 
attributes may change in 
culture 
(Fitzgerald et al., 
2004; Bush et al., 
2005; Jeffrey and 
Aspden, 2006; 
Gabriel et al., 
2010) 
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Table 2 890 
Osteoarthritic synovial fluid interleukin (IL)-1β and tumour necrosis factor (TNF)-α 891 
concentrations in vivo 892 
Condition 
Cytokine 
IL-1β TNF-α 
Control (human)  
(Kahle et al., 1992) 
<20 pg/mL 2890 pg/mL 
Control (canine)  
(Fujita et al., 2005) 
490 pg/mL 
105.3 
pg/mL 
OA (human)  
(Kahle et al., 1992) 
21 pg/mL 80 pg/mL 
OA - Hip dysplasia (canine) 
(Fujita et al., 2005) 
2010 pg/mL 600 pg/mL 
OA - Mild (porcine)  
(McNulty et al., 2013) 
109 pg/mL - 
OA - Moderate (porcine)  
(McNulty et al., 2013) 
122 pg/mL - 
  893 
Page 34 of 36
35 
 
Table 3 894 
A summary of load-induced changes in OA models 895 
Species 
studied 
Regimen tested 
Duration of 
experiment 
Findings of experiment Citation 
Dog (in vivo) 20-40 km/day 15 weeks 
Increased water content. 
Decreased collagen content. 
Decreased proteoglycan content. 
(Kiviranta 
et al., 
1992) 
Bovine 
explant 
Six on-off 
cycles of 30-
50% strain 
5 min 
compression: 
25 min release 
Apoptosis of cells. 
Degradation of collagen network. 
Glycosaminoglycan release. 
(Loening 
et al., 
2000) 
Bovine 
explant 
100 g, 500 g 
and 1 kg 
dropped from 2, 
5, 10 and 20 cm 
N/A 
Linear decrease in cell viability. 
Increased hydration of tissue. 
Partial depth fissures. 
(Jeffrey et 
al., 1995) 
Canine 
shoulder 
explant 
5 MPa at 0.3 Hz 20 or 120 min 
Cell death increased with 
increased loading time. 
Glycosaminoglycan and NO 
were not significantly altered. 
(Levin et 
al., 2001) 
Canine 
shoulder 
explant 
5 MPa at 0.3 Hz 
0, 2, 20, 120 
min 
Necrosis and apoptosis of cells 
increased with loading time. 
Proteoglycan increased in 2 and 
20 minute groups but decreased 
at 120 minutes. 
(Chen et 
al., 2001) 
Agarose 
embedded 
equine 
chondrocytes 
15% strain 
either statically 
or cyclically 
(0.3-3 Hz) 
48 h 
Dynamic strain increased cell 
proliferation. 
Static strain decreased 
glycosaminoglycan content, 
while cyclic strain increased 
glycosaminoglycan. 
(Lee and 
Bader, 
1997) 
Bovine 
explant 
25-50% strain 
over 3 min 
period 
Maintained for 
1, 2, 4, 8 and 24 
h 
Relative expression of matrix 
genes decreased. 
Relative expression of proteases 
increased. 
(Fitzgerald 
et al., 
2004) 
Human 
chondrocyte 
monolayer 
1, 5 or 10 MPa 
hydrostatic 
pressure at 1 Hz 
4 h per day for 
either 1 or 4 
days 
mRNA and protein expression of 
aggrecan and collagen type 2 
upregulated after 4 days. 
No difference at 1 day. 
(Ikenoue et 
al., 2003) 
Full 
thickness 
human 
cartilage 
explant 
Single 
mechanical load 
of 14 MPa for 
500 ms 
Measurements 
taken 96 h after 
injury 
DNA fragmentation in 34% of 
loaded chondrocytes (vs. 4% of 
control) 
GAG release increased in loaded 
explants (1.9% vs. 0.8% total 
GAG content) 
(D’Lima et 
al., 2001) 
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 897 
Figure legends 898 
 899 
Fig. 1. Healthy and diseased synovial joint showing the changes in the entire joint organ. 900 
Bone weakness and wearing has been reported, as well as synovial thickening and swelling, 901 
subchondral bone thickening, osteophyte formation and cartilage degradation. In addition, 902 
tendons can become weak and inflamed and ligaments can become lax.  903 
 904 
Fig. 2. Mechanistic pathways of in vitro models of OA. Both cytokines (a) and injurious 905 
loading (b) combine to cause the typical OA-like phenotype, showing apoptosis of cells, 906 
tissue degradation and inflammatory gene expression. In these cases, feedback loops occur 907 
either through inflammation, causing further cytokine stimulation, or abnormal loading, 908 
caused by tissue degradation. However, normal homeostatic loading is vital to tissue health, 909 
and works through similar pathways, as shown by the green line in (c), leading to tissue 910 
growth.  911 
 912 
MAPK, mitogen-activated protein-kinase; JNK, c-Jun N-terminal kinase; AP-1, activator 913 
protein-1; NFκB, nuclear factor kappa B; COX2, cyclooxygenase-2; PGE2, prostaglandin-E2; 914 
MMP, matrix metalloproteinase; ADAMTS, a distintegrin and metalloproteinase with a 915 
thrombospondin motif; ROS, reactive oxygen species. 916 
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